WO2009016498A8 - Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions - Google Patents

Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions Download PDF

Info

Publication number
WO2009016498A8
WO2009016498A8 PCT/IB2008/002046 IB2008002046W WO2009016498A8 WO 2009016498 A8 WO2009016498 A8 WO 2009016498A8 IB 2008002046 W IB2008002046 W IB 2008002046W WO 2009016498 A8 WO2009016498 A8 WO 2009016498A8
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
pyrimidine
pharmaceutical use
pyridine derivatives
compounds
Prior art date
Application number
PCT/IB2008/002046
Other languages
French (fr)
Other versions
WO2009016498A1 (en
Inventor
Mark E. Schnute
Jeffery Neal Carroll
Cathleen Elizabeth Hanau
Matthew David Mcreynolds
Jeffrey Allen Scholten
Joseph J. Mcdonald
Margaret L. Grapperhaus
Mark Alan Massa
Peter G. Ruminski
Michelle Ann Schmidt
Joseph Walter Strohbach
Bruce Cameron Hamper
Theresa R. Fletcher
Michael David Rogers
Patrick Michael O'brien
Joe Nahra
Mark Anthony Morris
William Howard Roark
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to EP08789003A priority Critical patent/EP2185537A1/en
Priority to AU2008281509A priority patent/AU2008281509A1/en
Priority to MX2010001338A priority patent/MX2010001338A/en
Priority to JP2010518770A priority patent/JP2010535192A/en
Priority to CN200880110131A priority patent/CN101815710A/en
Priority to CA2695304A priority patent/CA2695304A1/en
Publication of WO2009016498A1 publication Critical patent/WO2009016498A1/en
Publication of WO2009016498A8 publication Critical patent/WO2009016498A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The prsent invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as anti-inflammatory agents.
PCT/IB2008/002046 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions WO2009016498A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP08789003A EP2185537A1 (en) 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
AU2008281509A AU2008281509A1 (en) 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
MX2010001338A MX2010001338A (en) 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions.
JP2010518770A JP2010535192A (en) 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical uses and compositions
CN200880110131A CN101815710A (en) 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
CA2695304A CA2695304A1 (en) 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95360407P 2007-08-02 2007-08-02
US60/953,604 2007-08-02
US1553307P 2007-12-20 2007-12-20
US61/015,533 2007-12-20

Publications (2)

Publication Number Publication Date
WO2009016498A1 WO2009016498A1 (en) 2009-02-05
WO2009016498A8 true WO2009016498A8 (en) 2010-11-11

Family

ID=39884254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002046 WO2009016498A1 (en) 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions

Country Status (8)

Country Link
EP (1) EP2185537A1 (en)
JP (1) JP2010535192A (en)
KR (1) KR20100045497A (en)
CN (1) CN101815710A (en)
AU (1) AU2008281509A1 (en)
CA (1) CA2695304A1 (en)
MX (1) MX2010001338A (en)
WO (1) WO2009016498A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012035421A2 (en) * 2010-09-17 2012-03-22 Purdue Pharma L.P. Pyridine compounds and the uses thereof
AR086113A1 (en) * 2011-04-30 2013-11-20 Abbott Lab ISOXAZOLINS AS THERAPEUTIC AGENTS
WO2015070366A1 (en) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US9815796B2 (en) * 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
RU2019100559A (en) 2016-07-14 2020-07-14 Пфайзер Инк. NEW PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF THE ENZYM VANIN-1
CN111574405A (en) * 2020-06-11 2020-08-25 烟台显华化工科技有限公司 Diene negative liquid crystal compound and preparation method and application thereof
US20230113202A1 (en) * 2021-02-02 2023-04-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2023238930A1 (en) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 Analogues of azabicyclic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
PA8578101A1 (en) * 2002-08-13 2004-05-07 Warner Lambert Co HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
WO2006061706A1 (en) * 2004-12-08 2006-06-15 Warner-Lambert Company Llc Tetrazolyl-methylene amino acid derivatives

Also Published As

Publication number Publication date
CN101815710A (en) 2010-08-25
WO2009016498A1 (en) 2009-02-05
AU2008281509A1 (en) 2009-02-05
EP2185537A1 (en) 2010-05-19
JP2010535192A (en) 2010-11-18
CA2695304A1 (en) 2009-02-05
MX2010001338A (en) 2010-04-21
KR20100045497A (en) 2010-05-03

Similar Documents

Publication Publication Date Title
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008035359A3 (en) Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
WO2008013838A3 (en) Pyridizinone derivatives
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007089768A3 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2010038081A3 (en) 4-amino-5- (hetero) aryl-2-phenylamino-pyrimidine or pyridine and their use as dna gyrase and/or topoisomerase iv inhibitors
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
MX2012000414A (en) Pyridin-4-yl derivatives.
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2007115077A3 (en) Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
WO2010084115A3 (en) Antiviral agents
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
MX2011011428A (en) Sulfamoyl benzoic acid derivatives as trpm8 antagonists.
WO2013004995A8 (en) Pyrimidinone compounds and their use
UA92670C2 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists , pharmaceutical use thereof, composition based thereon
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
WO2009125434A3 (en) Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
WO2009013545A3 (en) Chemical compounds
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2008074833A3 (en) Compounds
WO2011087712A3 (en) Tricyclic derivatives and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880110131.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08789003

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 203645

Country of ref document: IL

Ref document number: 2695304

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010518770

Country of ref document: JP

Ref document number: MX/A/2010/001338

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008281509

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1188/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase in:

Ref document number: 20107004592

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008789003

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2008281509

Country of ref document: AU

Date of ref document: 20080729

Kind code of ref document: A